This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Top Research Reports for SAP, Novo Nordisk & Thermo Fisher
by Mark Vickery
SAP gains on cloud strength, NVO faces obesity setbacks, and TMO leans on AI and innovation amid macro headwinds.
NVOPositive Net Change TMONegative Net Change SAPPositive Net Change PSXPositive Net Change CGPositive Net Change HUBSPositive Net Change HURCNegative Net Change FONRNegative Net Change
computers industrial-products medical medical-devices pharmaceuticals
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
by Zacks Equity Research
Shares of ProKidney jump 515% after its kidney cell therapy shows strong efficacy in a Phase II diabetes-related CKD study.
AGENPositive Net Change AMRNPositive Net Change PROKPositive Net Change
medical
Brookdale's Occupancy Registers a Rise to 80.5% in June 2025
by Zacks Equity Research
BKD's June occupancy improves 230 bps year over year to 80.5%, driven by stronger move-ins and move-out activity across its senior living communities.
BKDPositive Net Change ADUSPositive Net Change MEDPNegative Net Change HIMSPositive Net Change
medical
AMN Stock Gains Post Latest Deals With symplr to Boost Operations
by Zacks Equity Research
AMN Healthcare sells Smart Square to symplr for $75 million and forms a new technology partnership aimed at boosting scheduling efficiency.
BSXPositive Net Change CORPositive Net Change AMNNegative Net Change ITGRPositive Net Change
medical medical-devices
Here's Why You Should Add PacBio Stock to Your Portfolio Now
by Zacks Equity Research
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset macroeconomic concerns and drive 2025 growth.
CORPositive Net Change PACBNegative Net Change ITGRPositive Net Change HIMSPositive Net Change
medical medical-devices
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
by Zacks Equity Research
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
BAYRYPositive Net Change VRNAPositive Net Change RXRXPositive Net Change RLYBNegative Net Change
biotechnology biotechs medical pharmaceuticals
Veeva Expands Market Reach Through Targeted Strategic Partnerships
by Harshit Gupta
VEEV gains momentum in 2025 with strategic partnerships fueling growth in AI, clinical research, and compliance.
ORCLPositive Net Change VEEVPositive Net Change IQVNegative Net Change
medical medical-devices
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
by Ahan Chakraborty
NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
by Zacks Equity Research
BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.
RHHBYPositive Net Change BMYPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck
by Zacks Equity Research
VRNA jumps 20% after Merck unveils buyout to add COPD drug Ohtuvayre and reduce its reliance on Keytruda.
SNYPositive Net Change MRKPositive Net Change LLYPositive Net Change VRNAPositive Net Change
biotechs medical pharmaceuticals
Alcon Stock Gains Following UNITY VCS' Approval in Canada
by Zacks Equity Research
ALC's UNITY VCS gets Canada's approval, advancing surgical precision with faster, more efficient technology.
ABTNegative Net Change ALGNPositive Net Change ALCNegative Net Change CORPositive Net Change
medical
Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now?
by Zacks Equity Research
TMO's growth via acquisitions and product launches is strong, but macro pressures and FX headwinds cloud the outlook.
TMONegative Net Change CAHNegative Net Change CORPositive Net Change PAHCPositive Net Change
medical medical-devices
Invest in 4 Winning Stocks With Proven Relative Price Power
by Nilanjan Choudhury
DELL, JBL, PAHC, and HBM are showing strong relative price strength and upward earnings estimates amid a rising market.
DELLPositive Net Change JBLNegative Net Change HBMNegative Net Change PAHCPositive Net Change
basic-materials computers medical
Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks
by Zacks Equity Research
GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.
JNJPositive Net Change ALCNegative Net Change GKOSPositive Net Change SGHTNegative Net Change
medical medical-devices
Is CVS Moving Closer to Reaching Its Long-Term Low 3X Leverage Goal?
by Moumi Mondal
CVS Health inches closer to its long-term leverage target, helped by Aetna margin recovery and disciplined cash use.
UNHNegative Net Change CINegative Net Change CVSNegative Net Change
medical medical-devices
Is the Options Market Predicting a Spike in AdaptHealth Stock?
by Zacks Equity Research
Investors need to pay close attention to AHCO stock based on the movements in the options market lately.
AHCONegative Net Change
medical medical-devices
Top Analyst Reports for T-Mobile, AstraZeneca & Comcast
by Mark Vickery
TMUS, AZN, and CMCSA each face market headwinds, but new analyst reports highlight strengths shaping their outlooks.
AZNPositive Net Change ETRPositive Net Change CMCSANegative Net Change UHSPositive Net Change ALGNPositive Net Change TMUSNegative Net Change
communications consumer-discretionary medical
2 Small-Cap Stocks That Appear Ready to Surge (STKS, LGCY)
by Ethan Feller
The ONE Group Hospitality and Legacy Education Inc. stocks boast a compelling mix is strong growth forecasts, reasonable valuations and improving analyst sentiment
LGCYPositive Net Change STKSPositive Net Change
medical restaurants
VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait?
by Harshit Gupta
Veeva Systems gains momentum as strong earnings, Vault CRM growth, and new AI tools reinforce its life sciences edge.
VEEVPositive Net Change IQVNegative Net Change HCATNegative Net Change CERTPositive Net Change
medical medical-devices
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success
by Zacks Equity Research
Cogent Biosciences stock jumps 23.4% after bezuclastinib hits primary and all key secondary endpoints in a phase III systemic mastocytosis study.
BAYRYPositive Net Change COGTPositive Net Change VRNAPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy
by Zacks Equity Research
Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.
BAYRYPositive Net Change MBIOPositive Net Change VRNAPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review
by Zacks Equity Research
Denali's lead drug for Hunter syndrome wins FDA Priority Review, marking a key step toward commercial-stage status.
SNYPositive Net Change BIIBNegative Net Change DNLIPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
by Zacks Equity Research
GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Healthcare Hit Again: Molina Cuts Guidance, Echoing Centene and UNH
by Kaibalya Pravo Dey
MOH slashes 2025 EPS outlook by more than 10%, citing rising medical costs and echoing warnings from CNC and UnitedHealth.
UNHNegative Net Change MOHPositive Net Change CNCPositive Net Change
insurance medical
Is Hologic Stock's Low Valuation an Opportunity or a Value Trap?
by Moumi Mondal
HOLX trades below peers on P/S, but falling EPS, weak Breast Health sales and China risks cloud the outlook.
ABTNegative Net Change HOLXPositive Net Change QGENPositive Net Change
medical medical-devices